Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to determine the safety and efficacy of teriflunomide
in multiple sclerosis (MS) with relapses.
Secondary objectives were:
- To determine the effect of teriflunomide on additional magnetic resonance imaging (MRI)
variables as well as clinical and quality of life measures.
- To investigate the pharmacokinetic and pharmacodynamic relationships.